Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

Pier Luigi Zinzani; Lapo Alinari; Monica Tani; Mariapaola Fina; Stefano Pileri; Michele Baccarani

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

Pier Luigi Zinzani, Lapo Alinari, Monica Tani, Mariapaola Fina, Stefano Pileri, Michele Baccarani

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

Original language	English
Pages (from-to)	702-703
Number of pages	2
Journal	Haematologica
Volume	90
Issue number	5
Publication status	Published - May 2005

Keywords

Alemtuzumab
CTCL
Low-dose
PTCL

ASJC Scopus subject areas

Hematology

Cite this

@article{9c43fa4a625e42d9a4742e374eed1300,

title = "Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma",

abstract = "We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.",

keywords = "Alemtuzumab, CTCL, Low-dose, PTCL",

author = "Zinzani, {Pier Luigi} and Lapo Alinari and Monica Tani and Mariapaola Fina and Stefano Pileri and Michele Baccarani",

year = "2005",

month = may,

language = "English",

volume = "90",

pages = "702--703",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "5",

}

TY - JOUR

T1 - Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

AU - Zinzani, Pier Luigi

AU - Alinari, Lapo

AU - Tani, Monica

AU - Fina, Mariapaola

AU - Pileri, Stefano

AU - Baccarani, Michele

PY - 2005/5

Y1 - 2005/5

N2 - We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

AB - We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.

KW - Alemtuzumab

KW - CTCL

KW - Low-dose

KW - PTCL

UR - http://www.scopus.com/inward/record.url?scp=20344379951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344379951&partnerID=8YFLogxK

M3 - Article

C2 - 15921394

AN - SCOPUS:20344379951

VL - 90

SP - 702

EP - 703

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 5

ER -

Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this